BIOMIND

The next generation of pharma.

Discover the Future

Biomind Labs is developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules.

BIOMIND

Research
& Development

We focus our research in transforming biomedical sciences knowledge into fast-acting/controlled-release psychedelics and tailored drug delivery systems targeting specific therapeutic indications that go beyond mental health conditions.

Our commitment is to provide patients and the psychiatric community with novel pharmaceuticals that provide a comfortable, safe and efficient use, by developing:

01

A unique portfolio of potent psychedelic molecules aimed at providing patients with access to affordable and modern day neuropsychiatric treatments

research
02

The most diversified pipeline of clinical trials targeting multiple diseases to seek fast-track approvals and breakthrough therapy designations for novel pharmaceuticals

research
03

Complex products, on-demand products, and customized products, controlling the time and place of drug release for the specific needs of each patient

research
04

A personalized medicine and a sustainable production to provide a democratic access to our novel pharmaceuticals regardless the income level of patients

research

Following strict scientific standards to protect patients and help produce reliable clinical trials results

Program
Evaluation
Pre-clinical
Phase I
Phase II
Phase III
Ayahuasca Treatment-Resistant Depression
BMND01 - DMT Treatment-Resistant Depression
BMND02 - DMT Fibromyalgia
BMND03 - DMT Addictive Disorders
BMND04 - 5-MeO-DMT Eating Disorders
BMND05 - 5-MeO-DMT Chronic Pain
BMND06 - Mescaline Inflammation
BMND07 - DMT Combination drug Major Depressive Disorder

A Robust
IP Strategy

Across every stage of the molecule to market lifecycle.
While during the last 60 years the psychedelic provisional applications average was one per year, Biomind Labs is filing the same number of applications of the last six decades, in 24 months.

3 Q2 2021
7 Q3 2021
10 Q4 2021
12 Q1 2022
15 Q2 2022
18 Q3 2022
22 Q4 2022

Our academic & corporate credentials

Our highly qualified team of scientists with more than fifteen years of experience on psychedelic research, leaded by the neuroscientist who completed the first randomized, placebo controlled clinical trial to test a psychedelic substance in treatment-resistant depression in 2016, aims to go beyond behavioural studies and work on elucidating the biochemical and neurological mechanisms of psychedelics, targeting new therapeutic indications outside mental conditions. A novel approach that positions Biomind as a game changer accross the pharmaceutical side of the psychedelic industry.

An experienced Board and Management with diverse public company experience, life sciences domain expertise form the Department of Neurology at Harvard Medical School and proven experience working with psychotropic substances in several jurisdictions and negotiating with government authorities and health agencies.

avatar

Discover Our Team

Alejandro Antalich

Chief Executive Officer & Director

Mr. Antalich is the former Chief Executive Officer of ICC Labs Inc. (TSXV), the first publicly traded company in the world to sell cannabis to a federal government. Through strategic foresight, determination, commitment, responsibility, teamwork and passion, he led ICC Labs to its successful sale to Aurora Cannabis (TSX) in November 2018. An entrepreneur with a commercial instinct and vision towards business growth, with expertise in the pharmaceutical industry, operations, manufacturing and product development. A savvy negotiator that manages unique relationship building skills. He led the negotiations of a multimillion transaction with one of the largest participants in the cannabis industry.

Oscar León

Chief Financial Officer & Director

A highly experienced Certified Public Accountant with a solid background in Financial Management, Accounting, Project Finance and Risk Analysis, with experience in Agriculture, Cannabis, Mining and Hydropower Industries. US/Canadian GAAP, IFRS knowledge, SEC and TSX reporting and filing experience. Strong sense of teamwork, quality and ethics. A results-oriented individual who demonstrates his abilities to the benefit of the organization. 3+ decades of experience as Certified Public Accountant. 2+ decades of experience as CFO, Financial Controller, Chief Accountant for several Uruguayan, Canadian and American Companies.

Paola Díaz Dellavalle

Chief Scientific Officer

Ms. Díaz Dellavalle has a Ph.D in chemistry and natural molecules with more than 15 years of experience in research, development, and management in biotechnology projects. She has studies in intellectual property and competitive intelligence analysis, with vast experience in patent strategy and technology transfer, specializing in the fields of chemistry, life sciences, pharmacy and biotechnology. During her career, she has led teams of scientists and managed subcontractors for non-clinical studies and new molecule development programs.

Juan Presa

Chief Legal Officer

Attorney at law from the Catholic University in Uruguay, specializing in corporate, commercial and international law. Juan has worked with companies from diverse industries such as agriculture, mining, cannabis, FinTech, including listed companies both on the New York Stock Exchange and the Toronto Stock Exchange. Juan developed the business expansion of companies through South America, Asia-Pacific and Africa, and participating in mergers and acquisitions of both public and private companies, public offerings and private placement financings.

Draulio Barros de Araujo

Scientific and Clinical Advisor

Dr. Draulio Barros de Araujo has graduated in Physics in 1995 at the University of Brasilia, has a master’s degree in applied physics and completed his Ph.D in physics applied to medicine and biology in 2002, working with functional neuroimaging (fMRI, EEG, MEG). He has a post-doctorate in radiology. Since 2009 Dr. Araujo works as a full professor of neuroscience at the Brain Institute, University of Rio Grande do Norte (UFRN), in Brazil. From 2017 to 2019 Dr. Araujo held a Fulbright visiting scholar position at the Department of Psychological and Brain Sciences of the University of California Santa Barbara, USA. Since 2006, Dr. Araujo’ research has focused on using functional neuroimaging methods (EEG and fMRI) to investigate the acute and lasting effects of the psychedelic ayahuasca, as well as its antidepressant effects. In 2015 he has published the results of a first open label trial with ayahuasca in treatment resistant depression, and in 2018 he completed the first randomized controlled trial to test a psychedelic substance (ayahuasca) in treatment-resistance depression, the results of which support the safety and therapeutic value of ayahuasca to address treatment-resistant depression.

Lucía Minini

Scientific Laboratory Manager

Ms Minini has a Ph.D in Chemistry with a degree in Biochemistry. She has been working on drug research and development since 2011. Her expertise resides in active pharmaceutical ingredients discovery, isolation and evaluation of their activity.

Florencia Ferraro

Biomolecular Research Scientist

Ms Ferraro has a MSc in Chemistry oriented to Medicinal Chemistry with a degree in Biochemistry. She has been working on drug research and development since 2013, specializing in synthesis, characterization, and biological evaluation of active pharmaceutical ingredients, both in vitro and in silico.

Martín Daners

Head of Quality Assurance and Regulatory Affairs

Mr Daners is a Pharmaceutical Chemist, specialized in Hospital Pharmacy. He has more than 20 years of experience in the pharmaceutical industry, in areas of production, warehousing, research and development. Responsible for the implementation and certification of GxP and ISO standards, with vast experience registering pharmaceutical products under the health regulatory authority.

Marcelo Falchi

Head of the Psychiatry Research Unit

Dr. Falchi is a psychiatrist (and so far only) licensed Brazilian physician, since the 1960s, to prescribe and monitor sessions with LSD in healthy volunteers in a scientific study (article published by Cambridge University Press, 2021). He has been studying psychedelics since 2017 with projects about Ayahuasca, LSD and Ketamine.

Patricio Espinoza

Head of Intellectual Property

Mr Espinoza is a specialist in Intellectual Property and Innovation Management Systems with more than 20 years of international experience. He managed more than 100 projects in R&D with companies from diverse industries. He is a professor of business strategies, innovation, economy, finances, competitiveness and economic development. Mr. Espinoza has an MBA in Philosophy of Technology.

Pablo Miranda

Nanotechnology Technician

PMr Miranda is a Pharmaceutical Chemist, specialized in active compounds encapsulation with several systems such as liposomes, solid lipid nanoparticles and other pharmaceutically suitable bioavailability enhancing vehicles.

Analia Castro

Nanotechnology Technician

Ms Castro is a Biochemistry, with vast experience in the field of Nanomedicine, mainly synthesis and characterization of nanobiosystems, drug delivery and active targeting functionalization as an innovative approach for the medical and pharmaceutical industry.

Ravi Sood

Chairman of the Board

Mr. Sood is managing director of Signal 8 Limited based in Toronto, Canada. Founder of and the principal investor in several businesses in emerging markets and currently serves as Chairman of Jade Power Trust (TSXV) and Galane Gold Ltd. (TSXV) and as a director of Eve & Co Incorporated (TSXV). He was the founder and Chief Executive Officer of Navina Asset Management Inc., a global asset management firm headquartered in Toronto, Canada. Mr. Sood led the investment activities of Navina and its predecessor company, Lawrence Asset Management Inc., from its founding in 2001 until he sold the firm in 2010. Mr. Sood was educated at the University of Waterloo (B.Mathematics).

Dr. Ben Illigens

Director

Mr. Illigens is a clinician, clinical scientist, biostatistician, clinical informatician, clinical data scientist and teacher, with over 12 years experience in implementing life sciences, healthcare and digital technologies, innovative programs, products and services in the academic, the biotech, pharmaceutical, CRO and life sciences market in Europe, USA, Latin America and Asia. He was the Instructor in Neurology at the Harvard Medical School, Department of Neurology, in Boston from 2008 to 2018. He also managed the Autonomic Nervous Center of the Department of Neurology. Mr. Illigens created the first distance, blended-learning program at the Dresden International University in 2014.

Fraser Buchan

Director

Mr. Buchan began his career on the institutional sales desk at GMP Securities in Toronto followed by GMP Europe in London. Mr. Buchan has served as an executive of Newcastle Gold, Elgin Mining, Touchstone Gold and Andean Precious Metals, and has served as a director of several publicly traded companies. Most recently, Mr. Buchan co-founded Tradewind Markets in partnership with IEX Group and Sprott Inc. Backed by leading companies in the precious metals industry, Tradewind provides institutions with a suite of digital solutions in trading, supply chain management, settlement and custody of precious metals. Mr. Buchan holds a degree in Economics from McGill University.

News

BIOMIND

The next generation of pharma.

General enquiries — info@biomindlabs.com
Media enquiries — media@biomindlabs.com